NewsRoom Articles - Page 3 of 206

ThursdayJun 05, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M – $130M The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against…

WednesdayJun 04, 2025 10:30 am

Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value

NTRB listed on the Nasdaq in 2021, is trading above its IPO price, and hit an all-time high of $11.78 in January of this year Nutriband’s AVERSA abuse-deterrent patch technology is FDA-bound and could command a market potential as high as $800 million annually Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show, where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast to the conventional biotech playbook. As is typical, the topic of the article focused on Nutriband’s…

TuesdayJun 03, 2025 10:00 am

Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis

A recent study conducted by experts based at University of Nottingham in the UK has revealed that young individuals afflicted by certain kinds of cancer like bone malignancies take longer before being diagnosed. Cancer among children is now regarded to be a worldwide disease burden, and getting an early diagnosis has been made a priority. The researchers undertook their study in order to enable the broader research community to get an understanding of what kids and young people go through starting with the onset of symptoms to the point at which a cancer diagnosis is made. To this end, the…

FridayMay 30, 2025 10:00 am

Study Links Autism to Increased Risk of Developing Parkinson’s Disease

A recently conducted study by a team at Karolinska Institutet in Sweden has established a link between a diagnosis of autism spectrum disorder (ASD) to a heightened risk of Parkinson’s disease (PD). The research appeared in the journal JAMA Neurology. The research team believes the two conditions may share a number of underlying biological mechanisms. The team based their study on data on more than two million individuals born in Sweden in the years 1974-1999. The registry data tracked these individuals starting at age 20 and the researchers analyzed this data covering those years until 2022. The team was interested…

ThursdayMay 29, 2025 10:20 am

Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs

Alzamend Neuro tackles Alzheimer’s, BD, MDD and PTSD with breakthrough therapies. AL001 delivers improved brain targeting and fewer side effects than lithium carbonate. Phase II trials underway with support from Mass General and AI partner QMENTA. ALZN002 offers a novel, adjuvant-free immunotherapy for Alzheimer’s disease. Alzamend Neuro (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company tackling some of the most pressing neurological and psychiatric conditions of our time — including Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to “Make Alzheimer’s Just a Memory™,” the Atlanta-based company is advancing a robust pipeline…

ThursdayMay 29, 2025 10:00 am

University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy

Texas’ Cancer Prevention & Research Institute has awarded $3 million to the University of Houston to establish a biomarker core for cancer immunotherapy. The research institute has earned a reputation for funding research projects which are groundbreaking. The $3m is a fraction of its $93m total package earmarked for awarding grants to entities within the state. The biomarker core to be established is planned to be a cutting-edge facility in the state geared at availing researchers comprehensive biomarker screens for conducting proteomic cancer research, especially in the fields of cancer immunotherapy and cancer biology. The new facility will be the…

WednesdayMay 28, 2025 10:00 am

House Approves Reconciliation Bill, Health Insurance and Medicaid to Be Impacted

On May 22, the U.S. House of Representatives approved the reconciliation bill for the 2025 budget with a one-vote difference between those in support of the bill and those opposed to it. The American Hospital Association says this legislation is going to have notable impacts upon healthcare insurance and Medicaid. Rick Pollack, the CEO and President of AHA, wrote to Congress on the eve of the House vote. In that statement, he expressed the association’s concerns about several provisions focused on the health insurance marketplace and Medicaid. He pointed out that the reductions to Medicaid funding are likely to have…

WednesdayMay 28, 2025 9:45 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined with a prior strategic investment, for which a financing term sheet has also been signed, the total financing investment, assuming both are closed, represents an expected $10.3 million for HOPE acquisition funding, supporting initial acquisitions of Dura Medical, Kadima, and NeuroSpa clinics. The expanding HOPE clinic network will deliver neuroplastic therapies for depression and PTSD, including ketamine and TMS. NRx continues regulatory progress for NRX-100 (IV ketamine) and NRX-101 (oral bipolar depression therapy). The FDA waived NRx’s $4.3 million drug application fee, and patents could…

TuesdayMay 27, 2025 10:00 am

New Swallowable Pill Provides Real-Time Gut Inflammation Tracking

The GI tract and its components like the mucosal lining play an important role of preventing harmful substances from finding their way into the bloodstream. When this mucosal lining is compromised, serious consequences like the entry of undigested food, toxins and bacteria into the bloodstream result. “Leaky gut” is responsible for conditions like inflammatory bowel disease. Existing tools for monitoring the mucus lining in the gut have limitations, such as being invasive and not providing continuous tracking. Approaches like endoscopy also don’t provide data on the entire GI tract and the updates they provide don’t come in real time. There…

FridayMay 23, 2025 11:15 am

Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics

The overuse and misuse of antibiotics have led to the emergence of antibiotic-resistant bacteria, posing a significant threat to public health. Soligenix’s SGX943 is a novel broad-spectrum therapy designed to treat bacterial infections without relying on conventional antibiotics. Preclinical studies have demonstrated the efficacy of SGX943 in various models of bacterial infection. In the face of escalating antibiotic resistance, the medical community is urgently seeking alternative treatments for bacterial infections. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is at the forefront of this effort with its development of SGX943 (dusquetide), a novel broad-spectrum therapy designed to combat bacterial infections without relying…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value

Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis

Study Links Autism to Increased Risk of Developing Parkinson’s Disease

Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs

University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy

House Approves Reconciliation Bill, Health Insurance and Medicaid to Be Impacted

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

New Swallowable Pill Provides Real-Time Gut Inflammation Tracking

Soligenix Inc. (NASDAQ: SNGX) Innovative Treatment to Combat Bacterial Infection Fills Urgent Need for Alternatives to Antibiotics

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search